| Market Capitalization (Millions $) |
100 |
| Shares
Outstanding (Millions) |
4 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-7 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Cyclerion Therapeutics Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing treatments for serious and rare diseases. The company uses a transformative approach to target the underlying causes of diseases by developing innovative therapies that target the soluble guanylate cyclase (sGC) enzyme pathway.
Cyclerion Therapeutics aims to develop drugs that can enhance the sGC pathway, which plays a crucial role in numerous physiological processes. By modulating this pathway, the company aims to address conditions such as sickle cell disease, neurodegenerative diseases, fibrotic diseases, and others.
The company is dedicated to advancing its pipeline of novel therapies and has a diverse portfolio of development programs. Cyclerion Therapeutics collaborates and partners with other leading pharmaceutical companies to accelerate the development and commercialization of its treatments.
Overall, Cyclerion Therapeutics Inc. is committed to bringing innovative treatments to patients suffering from serious and rare diseases by targeting the underlying causes of these conditions through the modulation of the sGC pathway.
Company Address: 245 First Street, 18th Floor Cambridge 2142 MA
Company Phone Number: 327-8778 Stock Exchange / Ticker: NASDAQ CYCN
|
%
0.72%